- Edwards reports PROGRESS results: TAVR vs. Surveillance in moderate AS
Edwards reports PROGRESS results: TAVR vs. Surveillance in moderate AS

- GE HealthCare unveils Allia Celeo ceiling-mounted interventional system
GE HealthCare unveils Allia Celeo ceiling-mounted interventional system

- Boston Scientific and Blackstone Life Sciences co-fund VITALYST in $455M deal
Boston Scientific and Blackstone Life Sciences co-fund VITALYST in $455M deal

- Biotronik completes first human implants of LivIQ leadless pacemaker
Biotronik announced the successful first-in-human implantations of its LivIQ leadless pacemaker system. The implants came in Australia as part of the company’s BIO|CONCEPT.LivIQ study, a premarket clinical investigation designed to evaluate the system’s preliminary safety and performance. Dr. Paul G

- FDA clears RevealDX’s AI lung nodule diagnostic
RevealDX has obtained US Food and Drug Administration (FDA) clearance for RevealAI-Lung, an artificial intelligence (AI)-based software for lung nodule risk assessment. The Washington-based company’s Computer-Assisted Diagnostic (CADx) software is designed to analyse chest CT scans for lung nodules

- ReGelTec shows Percutaneous Hydrogel Implant improves chronic low back pain
ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced the publication of a journal article in Pain Physician demonstrating that its HYDRAFIL System for disc augmentation safely generated lasting c

- Medtronic advances its innovation strategy with intent to acquire CathWorks
Medtronic, a global leader in healthcare technology, announced it will exercise its option to acquire CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The intent to acquire CathWorks follows a 2022 strategic partn

- CraniUS closes $20M financing to support blood-brain barrier tech for drug delivery
CraniUS Therapeutics announced that it raised $20 million in a Series B financing round to accelerate its development of NeuroPass. NeuroPass is a fully implantable, skull-embedded platform. The Baltimore-based company designed it to bypass the blood-brain barrier (BBB). It could enable targeted dru

- Bluedrop Medical picks up $1.2M for diabetic foot ulcer detection tech
The Irish Independent reports that Bluedrop Medical secured approximately $1.2М in funding from Enterprise Ireland. Galway-based Bluedrop develops technology aimed at reducing the rate of preventable amputations for people living with diabetes. It develops of an internet of things (IOT)-enabled devi

- Boston Scientific invests $1.5B in TAVR developer MiRus
Boston Scientific announced that it invested $1.5 billion in transcatheter aortic valve replacement (TAVR) developer MiRus. Marlborough, Massachusetts–based Boston Scientific now has an equity stake in MiRus worth approximately 34%. The deal also includes an exclusive option to acquire MiRus’ Siegel

- Xeltis gains EU CE mark on positive trial data for vascular access graft
Xeltis has gained a European CE mark for aXess, with 12-month pivotal data of the vascular access graft for haemodialysis demonstrating strong and higher secondary patency versus conventional arteriovenous grafts (AVGs). Xeltis’s aXess is a bioabsorbable graft for haemodialysis that is injected unde

- EmStop initiates IDE study of novel embolic protection device
EmStop announced that it kicked off the CAPTURE-2 FDA investigational device exemption (IDE) study of its embolic protection system (EPS). CAPTURE-2 evaluates the safety and performance of the EPS, an investigational device for cerebral embolic protection designed to capture and remove debris that i












